



## Perioperative Anesthesia and Analgesia in Total Joint Arthroplasty Guidelines 2020

# Acetaminophen in Total Joint Arthroplasty: The Clinical Practice Guidelines of the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, Hip Society, and Knee Society



Yale A. Fillingham, MD <sup>a,\*</sup>, Charles P. Hannon, MD, MBA <sup>b</sup>, Greg A. Erens, MD <sup>c</sup>, AAHKS Anesthesia & Analgesia Clinical Practice Guideline Workgroup  
William G. Hamilton, MD <sup>i</sup>, Craig J. Della Valle, MD <sup>j</sup>

<sup>a</sup> Department of Orthopaedic Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH

<sup>b</sup> Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL

<sup>c</sup> Department of Orthopaedic Surgery, Emory University, Atlanta, GA

<sup>i</sup> Anderson Orthopedic Research Institute, Alexandria, VA

<sup>j</sup> Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL

## ARTICLE INFO

### Article history:

Received 23 April 2020

Accepted 18 May 2020

Available online 26 May 2020

The American Association of Hip and Knee Surgeons, The American Academy of Orthopaedic Surgeons (AAOS), The Hip Society, The Knee Society, and The American Society of Regional Anesthesia and Pain Medicine have worked together to develop evidence-based guidelines on the use of acetaminophen in primary total joint arthroplasty (TJA). The purpose of these guidelines is to improve the treatment of orthopedic surgical patients and reduce practice variation by promoting a multidisciplinary evidence-based approach on the use of acetaminophen following primary TJA.

The combined clinical practice guidelines are meant to address common and important questions related to the efficacy and safety of acetaminophen in primary TJA. Utilizing the “AAOS Clinical Practice Guidelines and Systematic Review Methodology,” the committee members completed a systematic review and meta-analyses to support the clinical practice guidelines [1]. For each question, we have provided a recommendation, assessed the strength of the

recommendation, and elaborated on the rationale of the recommendation, which should be interpreted in accordance with the “AAOS Clinical Practice Guidelines and Systematic Review Methodology” [1]. The current clinical practice guidelines were based on the available evidence, so future updates may become necessary as additional literature becomes available with future research.

### Guideline Question 1

For patients undergoing primary TJA, does perioperative intravenous (IV) or oral acetaminophen affect postoperative pain and/or opioid consumption?

### Response/Recommendation

Administration of IV or oral acetaminophen reduces pain and opioid consumption during the perioperative period of a primary TJA.

### Strength of Recommendation: Moderate

#### Rationale

We reviewed 17 randomized clinical trials that represented the best available evidence including 15 high quality and 2 moderate quality studies to assess the ability of IV or oral acetaminophen to reduce pain and/or opioid consumption during the perioperative period following TJA [2–18]. Among the included studies, 11 studies investigated IV acetaminophen compared to placebo, 5 studies investigated IV acetaminophen compared to oral acetaminophen, and 3 studies compared oral acetaminophen to placebo [2–18]. Despite the numerous high and moderate quality randomized clinical trials, only a limited amount of meta-analyses were able to

William G. Hamilton and Craig J. Della Valle are co-senior authors.

One or more of the authors of this paper have disclosed potential or pertinent conflicts of interest, which may include receipt of payment, either direct or indirect, institutional support, or association with an entity in the biomedical field which may be perceived to have potential conflict of interest with this work. For full disclosure statements refer to <https://doi.org/10.1016/j.arth.2020.05.030>.

\* Reprint requests: Yale A. Fillingham, MD, Department of Orthopaedic Surgery, Dartmouth-Hitchcock Medical Center, 1 Medical Center Drive, Lebanon, NH 03756.

<https://doi.org/10.1016/j.arth.2020.05.030>

0883-5403/© 2020 Elsevier Inc. All rights reserved.

be performed due to inconsistency in the reporting of outcomes and time points for reporting the outcomes.

IV acetaminophen has been shown with limited heterogeneity in direct meta-analyses to demonstrate favorable reductions in postoperative pain and opioid consumption compared to placebo. Among the studies reporting on postoperative pain, direct meta-analysis of IV acetaminophen demonstrated lower 6-hour sum of pain intensity differences (outcome is a 4-point scale that summarizes the treatment benefit over a specific time period) and postoperative pain scores (ie, visual analogue scale and numeric pain rating scale) between 24 and 48 hours compared to placebo following surgery. Additionally, direct meta-analysis of opioid consumption measured 24 hours following TJA had improved outcomes for IV acetaminophen compared to placebo.

Due to the lack of consistent outcomes, no meta-analysis could be performed comparing IV and oral acetaminophen. However, among the 5 high quality randomized clinical trials investigating the comparison of IV and oral acetaminophen, no difference was observed between the routes of administration to reduce postoperative pain and/or opioid consumption [4,9,10,14,17]. Similarly, no meta-analysis could be performed comparing oral acetaminophen and placebo. Only 3 high quality randomized studies were available to assess the ability of oral acetaminophen to reduce postoperative pain and/or opioid consumption compared to placebo [6,9,16]. Qualitative review of the available literature would suggest oral acetaminophen reduces postoperative pain and opioid consumption, but the results do not consistently favor oral acetaminophen over placebo at statistically significant levels.

Although IV acetaminophen has been shown to be superior to placebo and equivalent to oral acetaminophen with regards to reduction in postoperative pain and/or opioid consumption, the lack of overwhelming evidence supporting the superiority of oral acetaminophen compared to placebo has resulted in a downgrade of the recommendation from strong to moderate for oral acetaminophen. Furthermore, the strength of the recommendation for IV acetaminophen was downgraded from strong to moderate due to concerns regarding the significantly higher cost of IV acetaminophen compared to oral acetaminophen. However, the US Food and Drug Administration has granted approval for marketing of a generic IV acetaminophen starting in December 2020, which has the potential to dramatically reduce the cost and change the downgrade of the recommendation of IV acetaminophen.

#### Guideline Question 2

For patients undergoing primary TJA, does acetaminophen after discharge affect postoperative pain and/or opioid consumption?

#### Response/Recommendation

In the absence of reliable evidence, it is the opinion of the workgroup that oral acetaminophen may be used after discharge as part of a multimodal pain regimen, as it is a low-cost and low-risk treatment for pain after discharge from a primary TJA.

#### Strength of Recommendation: Consensus

#### Rationale

Oral acetaminophen has widely been accepted as a safe, effective, and low-cost analgesic medication. Despite the numerous high and moderate quality randomized clinical trials investigating perioperative acetaminophen in the setting of a primary TJA, we lack specific evidence to guide a recommendation on the use of oral acetaminophen after discharge. As a result, we must rely on the available

evidence regarding acetaminophen in the nonsurgical treatment of osteoarthritis and its use during the perioperative period of primary TJA to guide our recommendation. In the setting of nonsurgical treatment of osteoarthritis of the knee, direct meta-analysis of oral acetaminophen showed a significant improvement in pain and function compared to an oral placebo [19]. Finally, the results from the current clinical practice guidelines have shown the effectiveness of oral acetaminophen to reduce postoperative pain and opioid consumption during the inpatient period following primary TJA.

Although acetaminophen has not been proven to be effective in isolation for postoperative pain management following primary TJA, it has been demonstrated as an effective adjunct as part of a multimodal pain management protocol [20]. When used in conjunction with other nonopioid analgesic medications, patients experienced a decreased risk of medical complications [20]. Therefore, we can support the use of oral acetaminophen after discharge as part of a multimodal pain regimen.

#### Guideline Question 3

For patients undergoing primary TJA, does perioperative acetaminophen compared to placebo have an increased risk of postoperative complications?

#### Response/Recommendation

Administration of IV or oral acetaminophen does not increase the risk of complications following primary TJA.

#### Strength of Recommendation: Strong

#### Rationale

Among the reviewed high and moderate quality randomized clinical trials, 11 studies reported on complications related to the administration of acetaminophen [2–6,12,13,15–18]. Qualitative examination demonstrated no consistent difference among IV acetaminophen, oral acetaminophen, and placebo. Direct meta-analysis was only capable of being performed for IV acetaminophen, which showed no significant difference with regards to any complication (0.98 relative risk; 95% confidence interval 0.83–1.16) or vomiting (1.16 relative risk; 95% confidence interval 0.30–4.45). Therefore, IV and oral acetaminophen are considered to be safe analgesic medications to administer during the perioperative episode of a primary TJA.

#### Areas for Future Research

Although we had numerous high and moderate quality randomized clinical trials to formulate the clinical practice guidelines on the use of acetaminophen, we were presented with limitations in the available literature. We suggest that future research of acetaminophen should focus on the oral route of administration during the perioperative period and after discharge from a primary TJA. We have robust literature consistently demonstrating that IV acetaminophen is favored compared to placebo and no different compared to oral acetaminophen; however, the inconsistent outcomes of literature on oral acetaminophen compared to placebo limited our ability to provide a strong recommendation. As a result, additional high quality randomized clinical trials of oral acetaminophen compared to placebo would likely provide more consistent evidence for or against oral acetaminophen to strengthen the recommendation. Because acetaminophen has typically been prescribed as a fixed combination pill with an opioid, the literature investigating the isolated effect of oral

acetaminophen with hip and knee patients in an outpatient setting has been focused on the nonsurgical management of osteoarthritis. Therefore, future research on the utilization of oral acetaminophen after discharge from a primary TJA would allow for an evidence-based recommendation in a future clinical practice guideline.

### Peer Review Process

Following the committee's formulation of the Clinical Practice Guideline draft, it underwent a peer review by the board of directors from the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, and the Hip and Knee Societies. The AAOS Evidence-Based Quality and Value Committee reviewed the Clinical Practice Guideline draft for endorsement. Additionally, the publication of the systematic review and meta-analysis on acetaminophen in primary hip and knee arthroplasties that supported the formulation of the Clinical Practice Guideline has undergone peer review for publication.

### Food and Drug Administration Clearance Statement

Acetaminophen is a drug described in this Clinical Practice Guideline that has been approved by the Food and Drug Administration (FDA). The oral formulation has been approved for over-the-counter use. The IV formulation has been approved for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid medications, and fever reduction in adults and pediatric patients 2 years or older. IV acetaminophen has an FDA black-box warning for risk of medication errors and hepatotoxicity. According to the FDA, it is the prescribing physician's responsibility to ascertain the FDA clearance status for all medications prior to use in a clinical setting.

### Disclosure Requirement

All authors or contributors to the Clinical Practice Guideline have provided a disclosure statement in accordance with the publicly available AAOS Orthopaedic Disclosure Program. All authors and contributors attest that none of the disclosures present are relevant to the Clinical Practice Guidelines.

### Acknowledgments

The authors would like to thank the American Association of Hip and Knee Surgeons for providing the funding and administrative support. The authors would like to thank Jayson Murray, Kyle Mullen, Francisco Casambre, and Vidya Visvabharathy from the American Academy of Orthopaedic Surgeons Department of Research, Quality, and Scientific Affairs for their assistance with the analysis and guidance. Finally, the authors also thank the leadership of the American Association of Hip and Knee Surgeons, American Academy of Orthopaedic Surgeons, American Society of Regional Anesthesia and Pain Medicine, the Hip Society, and Knee Society for help with organizational support.

### References

- [1] American Academy of Orthopaedic Surgeons Clinical Practice Guideline and Systematic Review Methodology. <https://www.aaos.org/quality/research-resources/methodology/> [accessed 01.04.2020].

- [2] Camu F, Borgeat A, Heylen RJ, Viel EJ, Boye ME, Cheung RY. Parecoxib, propacetamol, and their combination for analgesia after total hip arthroplasty: a randomized non-inferiority trial. *Acta Anaesthesiol Scand* 2017;61:99–110. <https://doi.org/10.1111/aas.12841>.
- [3] Gupta A, Abubaker H, Demas E, Ahrendtsen L. A randomized trial comparing the safety and efficacy of intravenous ibuprofen versus ibuprofen and acetaminophen in knee or hip arthroplasty. *Pain Physician* 2016;19:349–56.
- [4] Hickman SR, Mathieson KM, Bradford LM, Garman CD, Gregg RW, Lukens DW. Randomized trial of oral versus intravenous acetaminophen for postoperative pain control. *Am J Health Syst Pharm* 2018;75:367–75. <https://doi.org/10.2146/ajhp170064>.
- [5] Jahr JS, Breitmeyer JB, Pan C, Royal MA, Ang RY. Safety and efficacy of intravenous acetaminophen in the elderly after major orthopedic surgery: subset data analysis from 3, randomized, placebo-controlled trials. *Am J Ther* 2012;19:66–75. <https://doi.org/10.1097/MJT.0b013e3182456810>.
- [6] Karvonen S, Salomaki T, Olkkola KT. Efficacy of oral paracetamol and ketoprofen for pain management after major orthopedic surgery. *Methods Find Exp Clin Pharmacol* 2008;30:703–6. <https://doi.org/10.1358/mf.2008.30.9.1316919>.
- [7] Koppert W, Frottsch K, Huzurudin N, Boswald W, Griessinger N, Weisbach V, et al. The effects of paracetamol and parecoxib on kidney function in elderly patients undergoing orthopedic surgery. *Anesth Analg* 2006;103:1170–6. <https://doi.org/10.1213/01.ane.0000244324.87947.29>.
- [8] Murata-Ooiwa M, Tsukada S, Wakui M. Intravenous acetaminophen in multimodal pain management for patients undergoing total knee arthroplasty: a randomized, double-blind, placebo-controlled trial. *J Arthroplasty* 2017;32:3024–8. <https://doi.org/10.1016/j.arth.2017.05.013>.
- [9] O'Neal JB, Freiberg AA, Yelle MD, Jiang Y, Zhang C, Gu Y, et al. Intravenous vs oral acetaminophen as an adjunct to multimodal analgesia after total knee arthroplasty: a prospective, randomized, double-blind clinical trial. *J Arthroplasty* 2017;32:3029–33. <https://doi.org/10.1016/j.arth.2017.05.019>.
- [10] Politi JR, Davis 2nd RL, Matka AK. Randomized prospective trial comparing the use of intravenous versus oral acetaminophen in total joint arthroplasty. *J Arthroplasty* 2017;32:1125–7. <https://doi.org/10.1016/j.arth.2016.10.018>.
- [11] Sinatra RS, Jahr JS, Reynolds L, Groudine SB, Royal MA, Breitmeyer JB, et al. Intravenous acetaminophen for pain after major orthopedic surgery: an expanded analysis. *Pain Pract* 2012;12:357–65. <https://doi.org/10.1111/j.1533-2500.2011.00514.x>.
- [12] Sinatra RS, Jahr JS, Reynolds LW, Viscusi ER, Groudine SB, Payen-Champonis C. Efficacy and safety of single and repeated administration of 1 gram intravenous acetaminophen injection (paracetamol) for pain management after major orthopedic surgery. *Anesthesiology* 2005;102:822–31. <https://doi.org/10.1097/0000542-200504000-00019>.
- [13] Singla NK, Hale ME, Davis JC, Bekker A, Gimbel J, Jahr J, et al. IV acetaminophen: efficacy of a single dose for postoperative pain after hip arthroplasty: subset data analysis of 2 unpublished randomized clinical trials. *Am J Ther* 2015;22:2–10. <https://doi.org/10.1097/MJT.0000000000000026>.
- [14] Suarez JC, Al-Mansoori AA, Kanwar S, Semien GA, Villa JM, McNamara CA, et al. Effectiveness of novel adjuncts in pain management following total knee arthroplasty: a randomized clinical trial. *J Arthroplasty* 2018;33:5136–41. <https://doi.org/10.1016/j.arth.2018.02.088>.
- [15] Takeda Y, Fukunishi S, Nishio S, Yoshiya S, Hashimoto K, Simura Y. Evaluating the effect of intravenous acetaminophen in multimodal analgesia after total hip arthroplasty: a randomized controlled trial. *J Arthroplasty* 2019;34:1155–61. <https://doi.org/10.1016/j.arth.2019.02.033>.
- [16] Thybo KH, Hagi-Pedersen D, Dahl JB, Wetterslev J, Nersesjan M, Jakobsen JC, et al. Effect of combination of paracetamol (acetaminophen) and ibuprofen vs either alone on patient-controlled morphine consumption in the first 24 hours after total hip arthroplasty: the PANSALD randomized clinical trial. *JAMA* 2019;321:562–71. <https://doi.org/10.1001/jama.2018.22039>.
- [17] Westrich GH, Birch GA, Muskat AR, Padgett DE, Goytizolo EA, Bostrom MP, et al. Intravenous vs oral acetaminophen as a component of multimodal analgesia after total hip arthroplasty: a randomized, blinded trial. *J Arthroplasty* 2019;34:S215–20. <https://doi.org/10.1016/j.arth.2019.02.030>.
- [18] Zhou TJ, Tang J, White PF. Propacetamol versus ketorolac for treatment of acute postoperative pain after total hip or knee replacement. *Anesth Analg* 2001;92:1569–75. <https://doi.org/10.1097/0000539-200106000-00044>.
- [19] Jevsevar DS, Shores PB, Mullen K, Schulte DM, Brown GA, Cummins DS. Mixed treatment comparisons for nonsurgical treatment of knee osteoarthritis: a network meta-analysis. *J Am Acad Orthop Surg* 2018;26:325–36. <https://doi.org/10.5435/JAAOS-D-17-00318>.
- [20] Memtsoudis SG, Poeran J, Zubizarreta N, Cozowicz C, Morwald EE, Mariano ER, et al. Association of multimodal pain management strategies with perioperative outcomes and resource utilization: a population-based study. *Anesthesiology* 2018;128:891–902. <https://doi.org/10.1097/ALN.0000000000002132>.